All-India Institute of Medical Sciences
Ansari Nagar, New Delhi-29
(RESEARCH SECTION)

Ref. No. 24/Prop./Ped. /NG/18-19/RS

Dated: 08.10.2018

Subject: Purchase of Whole Exome sequencing for the Deptt. of Peadiatics, AIIMS, New Delhi-29 on proprietary basis- <u>Inviting comments thereon.</u>

*****

The request has been received from Dr.Neerja Gupta, Assistant Professor, Deptt. of Pediatrics, AIIMS to purchase the subject item from M/s MedGenome Labs Pvt. Ltd. on proprietary basis. The proposal submitted by M/s MedGenome Labs Pvt. Ltd. and Performa Invoice and Departmental PAC certifications are attached.

The above documents are being uploaded for open information to submit objections, commets, if any, from any manufacturer regarding proprietary nature of the equipment/item within issue of 15 days giving reference **No. 24/Prop./Ped./NG/18-19/RS**. The comments should be received by office of Stores Officer (RS), Research Section at AIIMS on or before **24/12/2018 upto <u>12:00 p.m</u>.,** failing which it will be presumed that any other vendor is having no comment to offer and case will be decided on merits.

STORES OFFICER (RS)

<u>Encl</u>: Related documents enclosed.
1. PAC Certificate enclosed.
2. Performa Invoice

ALL INDIA INSTITUTE OF MEDICAL SCIENCES
ANSARI NAGAR, NEW DELHI-110029

PROPRIETORY/SPECIFIC BRAND GOODS CERTIFICATE

1. Item/Type/Model No. required alongwith specification.	Whole Exome Sequencing
2. Is the item a spare parts attachment or accessory for an existing equipment.	No.
3. Name of the manufacturers/supplier of the item proposed by the Indentor.	M/s MedGenome Labs Pvt. Ltd.
4. Are they sole providers/sold distributors of the item.	Yes for our specifications.
5. Is there any other item with similar/ equivalent specification available in the market to meet the job requirement envisaged. If the answer is yes, why the same can't be procured. Demanding officer should bring out comparative functional advantages/cost effectiveness of the recommended item from these offered by other.	Yes, similar items are available with other laboratories as well. However, after trying out all available options, other companies, the result from M/s MedGenome Labs Pvt. Ltd. were found to be most satisfactory. The functional advantages/cost effectiveness of the recommended items are- **The Technology Platform:** Illumina is the sole manufacture of HiSeqX and HiSeq 4000. MedGenome is the sole service provider of sequencing on HiSeqX and HiSeq 4000. There is no equivalence specification for HiSeqX and HiSeq 4000. **Quality Certification:** The lab is CAP/NABL certified, participating the proficiency testing as a part of the quality program. . The exome are CAP certified while the NABL certification have whole exome as a scope of the test. **Lab Location:** Bangalore based. Test will be performed in India. Lab has extensive experience in reporting minor allele frequency from Indian population. **Add on confirmation:** In addition to Exome sequencing, company will offer CNV analysis on the Exome data performed for the candidate genes. Sanger confirmation for ***ONE VARIANT*** if identified will be part of the project. Minor allele frequency from Indian population for the variant identified would be given along with the data
6. What were the efforts made to locate	We have experience of getting the test done in other

alternative source of supply or use other substitutes.	laboratories but their performance was found to be unsatisfactory
7. Why open/limited tender can't be resorted to, for locating alternative source.	The requirement of planned research will only be fulfilled with the specifications mentioned. Since the test is being used for evaluating huge numbers of genes and involve critical analysis, testing from other manufactures may render the test redundant. Moreover the additional advantages as mentioned above in point no. 5 are not covered by any other company.
8. Are the items certifying that the rates are reasonable or not.	Yes,(certificate enclosed)
9. Any other justification for procuring item from single source.	The above item is required for specific purpose of performing genome wide analysis, which is a very critical test and has implications for the research in the project and will ultimately help in patient management and counselling.

Signature of Indentor

(Demanding Officer)

वरिष्ठ सलाहकार/Assistant Professor
Division of Genetics, Old OT Block
आनुवंशिकी विभाग/Department of Pediatrics
अ.आ.आ.चि.वि. नई दिल्ली/A.I.I.M.S., New Delhi-29
DMC Regn. No. 16600

Dr. Madhumita Roy Chowdhury
Senior Scientist
Division of Genetics,
Department of Pediatrics
All India Institute of Medical Sciences
New Delhi - 110029

COUNTERSIGNED

डॉ. मधुलिका कबरा/Dr. Madhulika Kabra
प्रोफेसर/Professor
आनुवंशिकी प्रभाग (शिशु विभाग)
Division of Genetics (Dept. of Pediatrics)
अ.आ.आ.चि.वि., नई दिल्ली/A.I.I.M.S., New Delhi-29
DMC Regn. No. 16600

ALL INDIA INSTITUTE OF MEDICAL SCIENCES
ANSARI NAGAR, NEW DELHI-110029

Specifications

- DNA isolation from blood
  Exome capture (Sure Select V-5 Capture Kit.)
- Library preperation,
- Cluster generation,
- NGS Sequencing using 2x 150bp reads @ 100x (10GB) on Illumina Hiseq or XTen platforms.
- Bioinformatics analysis with illumina HiseqXten
- Phred quality score of Q30, for 85% of data.
- Output should be in form of raw reads (fastq format).
- The charges should be inclusive of Sanger validation for 1 variant.
- An Indian lab that has extensive experience in Exome processing and reporting minor ellele frequency from Indian population
- Test should be performed in India. Samples deportation and testing out of Indian Territory are not authorized.
- The performing lab should have NABL & CAP certification, as part of proficiency programme.
- The performing Lab should have extensive experience. Essentially over ten thousand exomes processing and in reporting minor allele frequency from Indian population.
- The service provider should use ultra-throughput sequencing system, HiSeqX (part of X ten) for higher data generation and to bring cost effectiveness.

Dr. Madhumita Roy Chowdhury
Senior Scientist
Division of Genetics,
Department of Pedistries
All India Institute of Medical Sciences

istered Office:
edGenome Labs Ltd.
rd Floor, Narayana Nethralaya Building,
Narayana Health City, # 258/A, Bommasandra,
Hosur Road, Bangalore - 560 099, India.
T: +91(0) 80 6715 4901
www.medgenome.com

MEDGENOME

illumina

July 10, 2018

Proprietary Letter

To Whom It May Concern

We, Illumina Singapore Pte. Ltd., a subsidiary of Illumina, Inc., a Delaware corporation, having its principal place of business at 11 Biopolis Way # 09-05 Helios, Singapore 138667, who is established and reputable manufacturers of Illumina Sequencing & Arrays Systems and the consumables for the Sequencing and Arrays Systems. Hereby, confirm that the following products are solely manufactured by Illumina, Inc., U.S.A. and /or Illumina Singapore Pte. Ltd. and is Proprietary technology of Illumina, Inc., U.S.A.

This is also to certify that M/s Medgenome Pvt. Ltd., is currently the only commercial service provider in India that has HiSeq 4000 & HiSeq X Ten in house.

CAT NO	DESCRIPTION
SY-401-4001	**HiSeq® 4000 Sequencing System** The Illumina HiSeq 4000 Sequencing System is a dual flow cell sequencing instrument. System includes workstation computer, touch screen monitor, HiSeq Control Software, installation kits and standards, installation and training, and 12 months warranty (including parts and labor).
SY-412-1001	**HiSeq X™ Sequencing System (as part of HiSeq X Ten)** HiSeq X is an ultra-high throughput sequencing system, which is sold in quantities of at least 10 units (HiSeq X Ten = collection of 10 HiSeq X). The system is designed for whole genome sequencing application only.

Yours faithfully,

Illumina Singapore Pte. Ltd.

Name: Tan Kah Ling, Mavis
Title: Senior Director, Finance, Asia Pacific
For and behalf of: Illumina Singapore Pte. Ltd.

COLLEGE of AMERICAN PATHOLOGISTS

CAP ACCREDITED

The College of American Pathologists
certifies that the laboratory named below

MedGenome Labs Private Limited
Bangalore, Kar, India
Ramprasad Vedam, PhD

CAP Number: 9302248
AU-ID: 1770581

has met all applicable standards for accreditation and is hereby accredited by the College of American Pathologists' Laboratory Accreditation Program. Reinspection should occur prior to September 7, 2019 to maintain accreditation.

Accreditation does not automatically survive a change in director, ownership, or location and assumes that all interim requirements are met.

Chair, Commission on Laboratory Accreditation

President, College of American Pathologists

National Accreditation Board for Testing and Calibration Laboratories
(A Constituent Board of Quality Council of India)

NABL

QCI

CERTIFICATE OF ACCREDITATION

MEDGENOME LABS PRIVATE LIMITED

has been assessed and accredited in accordance with the standard

ISO 15189:2012

"Medical laboratories - Requirements for quality and competence"

for its facilities at

SDF 17, 1st Floor, C-Block CSEZ, Cochin, Kerala

in the field of

MEDICAL TESTING

Certificate Number MC-2497

Issue Date 18/12/2017

Valid Until 17/12/2019

This certificate remains valid for the Scope of Accreditation as specified in the annexure subject to continued satisfactory compliance to the above standard & the relevant requirements of NABL.

(To see the scope of accreditation of this laboratory, you may also visit NABL website www.nabl-india.org)

Signed for and on behalf of NABL

Dr. Vandana Jain
Program Director

8907697030001000226

Anil Relia
Chief Executive Officer



National Accreditation Board for Testing and Calibration Laboratories

(A Constituent Board of Quality Council of India)

NABL

QCI

SCOPE OF ACCREDITATION

Laboratory Medgenome Labs Private Limited, SDF 17, 1st Floor, C-Block CSEZ, Cochin, Kerala

Accreditation Standard ISO 15189: 2012

Certificate Number MC-2497 Page 1 of 7

Validity 18.12.2017 to 17.12.2019 **Last Amended on** --

Sl.	Product / Material of Test	Specific Test Performed	Test Method	Range of Testing / Limits of Detection	CV%
			GENETICS		
1.	Blood/ Genomic DNA	*JAK2* gene analysis - 2 exons (12 & 14)	PCR and DNA sequencing	Qualitative within limits of Sanger sequencing	NA
2.	Blood/ FFPE/ Genomic DNA	*PDGFRA* gene analysis - 3 exons (12, 14 & 18)	PCR and DNA sequencing	Qualitative within limits of Sanger sequencing	NA
3.	Blood/ Genomic DNA	*TP53* gene analysis	PCR and DNA sequencing	Qualitative within limits of Sanger sequencing	NA
4.	Blood/ Genomic DNA	Congenital Adrenal Hyperplasia *CYP21A2* (21-0H) gene analysis	PCR and DNA sequencing	Qualitative within limits of Sanger sequencing	NA
5.	Blood/ Genomic DNA	*VHL* gene analysis	PCR and DNA sequencing	Qualitative within limits of Sanger sequencing	NA
6.	Blood/ Genomic DNA	Cystic fibrosis (*CFTR*) del508 mutation analysis	PCR and DNA sequencing	Qualitative within limits of Sanger sequencing	NA
7.	FFPE / Genomic DNA	*KIT* gene analysis - 4 exons (9, 11, 13 & 17)	PCR and DNA sequencing	Qualitative within limits of Sanger sequencing	NA
8.	Blood/RNA	Imatinib resistance (*ABL* kinase) gene analysis	PCR and DNA sequencing	Qualitative within limits of Sanger sequencing	NA
9.	Blood/ Genomic DNA	Factor V Leiden mutation analysis (exon 10)	PCR and DNA sequencing	Qualitative within limits of Sanger sequencing	NA
10.	Blood/ Genomic DNA	*MTHFR* gene analysis - 2 exons (5 & 8)	PCR and DNA sequencing	Qualitative within limits of Sanger sequencing	NA
11.	Blood/ Genomic DNA	Spinal Muscular Atrophy (*SMN1*) gene analysis	PCR and DNA sequencing	Qualitative within limits of Sanger sequencing	NA

Ashok Kumar Gogna
Convenor

Dr. Vandana Jain
Program Director

National Accreditation Board for Testing and Calibration Laboratories

(A Constituent Board of Quality Council of India)

SCOPE OF ACCREDITATION

Laboratory Medgenome Labs Private Limited, SDF 17, 1st Floor, C-Block CSEZ, Cochin, Kerala

Accreditation Standard ISO 15189: 2012

Certificate Number MC-2497 **Page 2 of 7**

Validity 18.12.2017 to 17.12.2019 **Last Amended on** --

Sl.	Product / Material of Test	Specific Test Performed	Test Method	Range of Testing / Limits of Detection	CV%
12.	FFPE / Genomic DNA	*IDH1* gene analysis	PCR and DNA sequencing	Qualitative within limits of Sanger sequencing	NA
13.	Blood/ Genomic DNA	Alpha Thalassemia gene analysis (*HBA1 & HBA2*)	PCR and DNA sequencing	Qualitative within limits of Sanger sequencing	NA
14.	Blood/ Genomic DNA	Beta Thalassemia (*HBB*) gene analysis	PCR and DNA sequencing	Qualitative within limits of Sanger sequencing	NA
15.	Blood/ Genomic DNA	*TSC1* & *TSC2* gene analysis	PCR and DNA sequencing	Qualitative within limits of Sanger sequencing	NA
16.	Blood/ Genomic DNA	*NOTCH3* (CADASIL) gene analysis -2 exons (2 & 3)	PCR and DNA sequencing	Qualitative within limits of Sanger sequencing	NA
17.	Blood/ Genomic DNA	*BRCA1* and *BRCA2* gene analysis	PCR and DNA sequencing	Qualitative within limits of Sanger sequencing	NA
18.	Blood/ Genomic DNA	*DPYD* mutation analysis (intron 14)	PCR and DNA sequencing	Qualitative within limits of Sanger sequencing	NA
19.	Blood/ Genomic DNA	Connexin-26(*GJB2*)gene analysis (exon 2)	PCR and DNA sequencing	Qualitative within limits of Sanger sequencing	NA
20.	Blood/ Genomic DNA	MPN reflex panel	PCR and DNA sequencing	Qualitative within limits of Sanger sequencing	NA
21.	Blood/ Genomic DNA	Sickle cell anemia (*HBB*) gene analysis (Exon 1)	PCR and DNA sequencing	Qualitative within limits of Sanger sequencing	NA
22.	Blood/ FFPE / Genomic DNA	*RET* oncogene - 8 exons(5,8,10,11,13,14,15 & 16)	PCR and DNA sequencing	Qualitative within limits of Sanger sequencing	NA
23.	Blood/ Genomic DNA	Cardiomyopathy predisposition - *MYBPC3* (25bp deletion)	PCR and DNA sequencing	Qualitative within limits of Sanger sequencing	NA
24.	Blood/ Genomic DNA	Clopidogrel dosage *CYP2C19*2* and *CYP2C19*3*	PCR and DNA sequencing	Qualitative within limits of Sanger sequencing	NA

Ashok Kumar Gogna
Convenor

Dr. Vandana Jain
Program Director

National Accreditation Board for Testing and Calibration Laboratories

(A Constituent Board of Quality Council of India)

SCOPE OF ACCREDITATION

Laboratory Medgenome Labs Private Limited, SDF 17, 1st Floor, C-Block CSEZ, Cochin, Kerala

Accreditation Standard ISO 15189: 2012

Certificate Number MC-2497 **Page 2 of 7**

Validity 18.12.2017 to 17.12.2019 **Last Amended on** --

Sl.	Product / Material of Test	Specific Test Performed	Test Method	Range of Testing / Limits of Detection	CV%
12.	FFPE / Genomic DNA	*IDH1* gene analysis	PCR and DNA sequencing	Qualitative within limits of Sanger sequencing	NA
13.	Blood/ Genomic DNA	Alpha Thalassemia gene analysis (*HBA1 & HBA2*)	PCR and DNA sequencing	Qualitative within limits of Sanger sequencing	NA
14.	Blood/ Genomic DNA	Beta Thalassemia (*HBB*) gene analysis	PCR and DNA sequencing	Qualitative within limits of Sanger sequencing	NA
15.	Blood/ Genomic DNA	*TSC1* & *TSC2* gene analysis	PCR and DNA sequencing	Qualitative within limits of Sanger sequencing	NA
16.	Blood/ Genomic DNA	*NOTCH3* (CADASIL) gene analysis -2 exons (2 & 3)	PCR and DNA sequencing	Qualitative within limits of Sanger sequencing	NA
17.	Blood/ Genomic DNA	*BRCA1* and *BRCA2* gene analysis	PCR and DNA sequencing	Qualitative within limits of Sanger sequencing	NA
18.	Blood/ Genomic DNA	*DPYD* mutation analysis (intron 14)	PCR and DNA sequencing	Qualitative within limits of Sanger sequencing	NA
19.	Blood/ Genomic DNA	Connexin-26(*GJB2*)gene analysis (exon 2)	PCR and DNA sequencing	Qualitative within limits of Sanger sequencing	NA
20.	Blood/ Genomic DNA	MPN reflex panel	PCR and DNA sequencing	Qualitative within limits of Sanger sequencing	NA
21.	Blood/ Genomic DNA	Sickle cell anemia (*HBB*) gene analysis (Exon 1)	PCR and DNA sequencing	Qualitative within limits of Sanger sequencing	NA
22.	Blood/ FFPE / Genomic DNA	*RET* oncogene - 8 exons(5,8,10,11,13,14,15 & 16)	PCR and DNA sequencing	Qualitative within limits of Sanger sequencing	NA
23.	Blood/ Genomic DNA	Cardiomyopathy predisposition - *MYBPC3* (25bp deletion)	PCR and DNA sequencing	Qualitative within limits of Sanger sequencing	NA
24.	Blood/ Genomic DNA	Clopidogrel dosage:*CYP2C19*2* and *CYP2C19*3*	PCR and DNA sequencing	Qualitative within limits of Sanger sequencing	NA

Ashok Kumar Gogna
Convenor

Dr. Vandana Jain
Program Director



National Accreditation Board for Testing and Calibration Laboratories

(A Constituent Board of Quality Council of India)

SCOPE OF ACCREDITATION

Laboratory Medgenome Labs Private Limited, SDF 17, 1st Floor, C-Block CSEZ, Cochin, Kerala

Accreditation Standard ISO 15189: 2012

Certificate Number MC-2497 Page 2 of 7

Validity 18.12.2017 to 17.12.2019 Last Amended on --

Sl.	Product / Material of Test	Specific Test Performed	Test Method	Range of Testing / Limits of Detection	CV%
12.	FFPE / Genomic DNA	*IDH1* gene analysis	PCR and DNA sequencing	Qualitative within limits of Sanger sequencing	NA
13.	Blood/ Genomic DNA	Alpha Thalassemia gene analysis (*HBA1* & *HBA2*)	PCR and DNA sequencing	Qualitative within limits of Sanger sequencing	NA
14.	Blood/ Genomic DNA	Beta Thalassemia (*HBB*) gene analysis	PCR and DNA sequencing	Qualitative within limits of Sanger sequencing	NA
15.	Blood/ Genomic DNA	*TSC1* & *TSC2* gene analysis	PCR and DNA sequencing	Qualitative within limits of Sanger sequencing	NA
16.	Blood/ Genomic DNA	*NOTCH3* (CADASIL) gene analysis -2 exons (2 & 3)	PCR and DNA sequencing	Qualitative within limits of Sanger sequencing	NA
17.	Blood/ Genomic DNA	*BRCA1* and *BRCA2* gene analysis	PCR and DNA sequencing	Qualitative within limits of Sanger sequencing	NA
18.	Blood/ Genomic DNA	*DPYD* mutation analysis (intron 14)	PCR and DNA sequencing	Qualitative within limits of Sanger sequencing	NA
19.	Blood/ Genomic DNA	Connexin-26(*GJB2*)gene analysis (exon 2)	PCR and DNA sequencing	Qualitative within limits of Sanger sequencing	NA
20.	Blood/ Genomic DNA	MPN reflex panel	PCR and DNA sequencing	Qualitative within limits of Sanger sequencing	NA
21.	Blood/ Genomic DNA	Sickle cell anemia (*HBB*) gene analysis (Exon 1)	PCR and DNA sequencing	Qualitative within limits of Sanger sequencing	NA
22.	Blood/ FFPE / Genomic DNA	*RET* oncogene - 8 exons(5,8,10,11,13,14,15 & 16)	PCR and DNA sequencing	Qualitative within limits of Sanger sequencing	NA
23.	Blood/ Genomic DNA	Cardiomyopathy predisposition - *MYBPC3* (25bp deletion)	PCR and DNA sequencing	Qualitative within limits of Sanger sequencing	NA
24.	Blood/ Genomic DNA	Clopidogrel dosage:*CYP2C19*2* and *CYP2C19*3*	PCR and DNA sequencing	Qualitative within limits of Sanger sequencing	NA

Ashok Kumar Gogna
Convenor

Dr. Vandana Jain
Program Director

National Accreditation Board for Testing and Calibration Laboratories

(A Constituent Board of Quality Council of India)

SCOPE OF ACCREDITATION

Laboratory Medgenome Labs Private Limited, SDF 17, 1st Floor, C-Block CSEZ, Cochin, Kerala

Accreditation Standard ISO 15189: 2012

Certificate Number MC-2497 **Page 5 of 7**

Validity 18.12.2017 to 17.12.2019 **Last Amended on** --

Sl.	Product / Material of Test	Specific Test Performed	Test Method	Range of Testing / Limits of Detection	CV%
45.	Blood/ Genomic DNA	Cystic fibrosis (*CFTR*) deletion/ duplication analysis	MLPA	Qualitative within limits of MLPA	NA
46.	Blood/ Genomic DNA	Androgen receptor (*AR*) deletion/ duplication analysis	MLPA	Qualitative within limits of MLPA	NA
47.	Blood/ Genomic DNA	Haemophilia (*F8*) deletion/duplication analysis	MLPA	Qualitative within limits of MLPA	NA
48.	Blood/ Genomic DNA	Dravet syndrome (*SCN1A*) deletion/duplication analysis	MLPA	Qualitative within limits of MLPA	NA
49.	Blood/ Genomic DNA	Pompe disease (*GAA*) deletion/ duplication analysis	MLPA	Qualitative within limits of MLPA	NA
50.	Blood/ Genomic DNA	GLUT1 deficiency (*SLC2A1*) deletion/duplication analysis	MLPA	Qualitative within limits of MLPA	NA
51.	Blood/ Genomic DNA	Glycine encephalopathy (*GLDC*) deletion/ duplication analysis	MLPA	Qualitative within limits of MLPA	NA
52.	Blood/ Genomic DNA	Neurometabolic disorder (*MLC1, L2HGDH, D2HGDH, MLYCD*) deletion duplication analysis	MLPA	Qualitative within limits of MLPA	NA
53.	Blood/ Genomic DNA	Menkes disease (*ATP7A*) deletion/ duplication analysis	MLPA	Qualitative within limits of MLPA	NA
54.	Blood/ Genomic DNA	*TSC1* and *TSC2* deletion/duplication analysis	MLPA	Qualitative within limits of MLPA	NA

Ashok Kumar Gogna
Convenor

Dr. Vandana Jain
Program Director

National Accreditation Board for Testing and Calibration Laboratories

(A Constituent Board of Quality Council of India)

SCOPE OF ACCREDITATION

Laboratory Medgenome Labs Private Limited, SDF 17, 1st Floor, C-Block CSEZ, Cochin, Kerala

Accreditation Standard ISO 15189: 2012

Certificate Number MC-2497 **Page 6 of 7**

Validity 18.12.2017 to 17.12.2019 **Last Amended on** --

Sl.	Product / Material of Test	Specific Test Performed	Test Method	Range of Testing / Limits of Detection	CV%
55.	Blood/ Genomic DNA	Krabbe disease (*GALC*) deletion/ duplication analysis	MLPA	Qualitative within limits of MLPA	NA
56.	Blood/ Genomic DNA	Pantothenate kinase-associated neurodegeneration (*PANK2*) deletion/ duplication analysis	MLPA	Qualitative within limits of MLPA	NA
57.	Blood/ Genomic DNA	Charcot-Marie-Tooth *PMP22* deletion/duplication analysis	MLPA	Qualitative within limits of MLPA	NA
58.	Blood/ Genomic DNA	Dysferlinopathy/LGM D2A (*CAPN3*) deletion/duplication analysis	MLPA	Qualitative within limits of MLPA	NA
59.	Blood/ Genomic DNA	Duchenne Muscular Dystrophy (*DMD*) deletion/duplication analysis	MLPA	Qualitative within limits of MLPA	NA
60.	Blood/ Genomic DNA	Congenital Muscular Dystrophy (*LAMA2*) deletion/duplication analysis	MLPA	Qualitative within limits of MLPA	NA
61.	Blood/ Genomic DNA	Dysferlinopathy/LGM D2B (*DYSF*) deletion/duplication analysis	MLPA	Qualitative within limits of MLPA	NA
62.	Blood/ Genomic DNA	*RB1* deletion/duplication analysis	MLPA	Qualitative within limits of MLPA	NA
63.	Blood/ Genomic DNA	*NF1* and *NF2* deletion/duplication analysis	MLPA	Qualitative within limits of MLPA	NA

Ashok Kumar Gogna
Convenor

Dr. Vandana Jain
Program Director



National Accreditation Board for Testing and Calibration Laboratories

(A Constituent Board of Quality Council of India)

SCOPE OF ACCREDITATION

Laboratory Medgenome Labs Private Limited, SDF 17, 1st Floor, C-Block CSEZ, Cochin, Kerala

Accreditation Standard ISO 15189: 2012

Certificate Number MC-2497 **Page 7 of 7**

Validity 18.12.2017 to 17.12.2019 **Last Amended on** --

Sl.	Product / Material of Test	Specific Test Performed	Test Method	Range of Testing / Limits of Detection	CV%
64.	Blood/ Genomic DNA	Spinal Muscular Atrophy (*SMN1/SMN2*) deletion/duplication analysis	MLPA	Qualitative within limits of MLPA	NA
65.	Blood/ Genomic DNA	Canavan disease (*ASPA*) deletion/ duplication analysis	MLPA	Qualitative within limits of MLPA	NA
66.	Blood/ Genomic DNA	Tay–Sachs disease (*HEXA*) deletion/ duplication analysis	MLPA	Qualitative within limits of MLPA	NA
67.	Blood/ Genomic DNA	Rett Syndrome (*MECP2*) deletion/ duplication analysis	MLPA	Qualitative within limits of MLPA	NA
68.	Blood/ Genomic DNA	X-linked spastic paraplegia-2 (*PLP1*) deletion/duplication analysis	MLPA	Qualitative within limits of MLPA	NA
69.	Blood/ Genomic DNA	*NDP* Gene Deletion/ Duplication Analysis	MLPA	Qualitative within limits of MLPA	NA

Ashok Kumar Gogna
Convenor

Dr. Vandana Jain
Program Director

Registered Office
MedGenome Labs Ltd.
3rd Floor, Narayana Nethralaya Building,
Narayana Health City, # 258/A, Bommasandra,
Hosur Road, Bangalore - 560 099. India.
T: +91(0)80 6715 4901
www.medgenome.com

MEDGENOME

Date: 27th November 2018

To Whom So Ever It May Concern

This is to certify that MedGenome Labs Ltd. is giving an undertaking that the prices quoted in this quotation are not higher than what we had quoted to other Government hospitals across the country in the Financial year 2018-2019.

If you need any further information, please feel free to contact us.

Thanking you,

For MedGenome Labs Ltd.

Authorized Signatory

Registered Office:
MedGenome Labs Ltd.
3rd Floor, Narayana Nethralaya Building,
Narayana Health City, # 258/A, Bommasandra,
Hosur Road, Bangalore - 560 099, India.
T: +91(0) 80 6715 4901
www.medgenome.com

MEDGENOME

Rate Quotation

Date: 27th November 2018

To,

Dr. Neerja Gupta
[MD (Pediatrics), DM (Medical Genetics)], Associate Professor, Department of Genetics
All India Institute of Medical Sciences & Research,
Ansari Nagar, New Delhi, Delhi 110029

DNA Sequencing & Analysis
Using Illumina HiSeqX and HiSeq XTen for Whole Exome

Description	Unit Price per Sample (INR)	Quantity	Price (INR)
DNA sequencing and analysis for Whole Exome panel. **Sample type:** Peripheral Blood 3-4 ml or > 100µL for DNA (EDTA Lavender top or DNA in sealed Eppendorf tube) • QC analysis of samples and Data • NGS Sequencing using 2x 150bp reads @ 100x on Illumina Hiseq or XTen platforms. • Bioinformatics analysis with Illumina HiseqXten • Clinical Report of 70 patients • Phred quality score of Q30, for 85% of data. • Raw data in fastq format • Turn Around Time 6-8 Week • Sanger confirmation for ONE VARIANT if identified will be part of the project. **Kit Used:** Sequencing libraries will be prepared using **Agilent-Sure Select V5** • 21,522 genes covered (coding regions and splice junctions) • Targeted exons – 3,57,999	27,000.00	70	18,90,000.00
Amount in words: Eighteen Lacs and Ninety Thousand only			18,90,000.00

Dr. Madhulika Kabra

डा. नीरजा गुप्ता/Dr. Neerja Gupta
सहायक आचार्य/Assistant Professor
आनुवंशिकी एवम् (समरोह चिकित्सा) विभाग
Division of Genetics (Deptt. of Pedi...
अ.भा.आ.सं., नई दिल्ली/A.I.I.M.S., New D...

MedGenome Labs Ltd

Registered Office:
MedGenome Labs Ltd.
3rd Floor, Narayana Nethralaya Building,
Narayana Health City, # 258/A, Bommasandra,
Hosur Road, Bangalore - 560 099, India.
T: +91(0) 80 6715 4901
www.medgenome.com

MEDGENOME

Payment Terms:

1. Order will be placed every 2- 3 months
2. Payment within 30 days of Invoice Submissions.
3. Cheque or DD issued in the name of **"MedGenome Labs Ltd."**, Payable at Bangalore
4. **RTGS/Bank details:**
   MedGenome Labs Ltd.
   Bank: HDFC
   Branch: RT Nagar, Bangalore
   Acc. No.: 50200012336370
   IFSC Code: HDFC0000140 MICR Code: 560240009

Validity: This proposal is valid for 90 days from the date of receipt

For any technical questions relating to this proposal, please contact:

Malaichamy Sivasankar (Senior Genome Analyst)

malaichamy.s@medgenome.com

For any commercial queries relating to this proposal, please contact:

Mr. Ravishankar
Business Development Manager
Mobile: +91-8285642099
E-mail: ravishankar.k@medgenome.com

Terms and Conditions:

1. The sample collection will be arranged by MedGenome Labs Ltd.
2. If the samples received do not meet the quality standards required to perform the service, the details will be intimated to the customer and further processing will be based on the instructions of the customers only.
3. The relevant a) Indent or Purchase Order (PO) b) Sample submission form and c) Customer Registration form/details (for new customer only) should be submitted along with samples.
4. The Turn Around Time (TAT) for the sample will be 6-8 Weeks after receiving the sample.
5. Our responsibility rests with only performing the services as outlined in this quotation, please note that the pricing and turnaround times provided in this financial proposal are estimates based on information provided by the client and are subject to change, with prior notification to the customer. MedGenome will invoice for all services and/or products provided. This could change if there is a project scope change.
6. This quotation with its contents and any correspondence in this regard are strictly confidential. The information contained in this quote cannot be shared with any other parties without expressed written consent from MedGenome. MedGenome reserves the right to pursue the fullest legal action against any violations of confidentiality and improper use or sharing of this quotation.
7. Any disputes arising out of the Contract shall be subject to the Jurisdiction of the Courts within the city of Bengaluru, Karnataka only.

Conclusion:
We hope that this proposal will meet your requirements. We will be glad to provide further explanations on any of the items mentioned here.

डॉ. नीरजा गुप्ता/Dr. Neerja Gupta
सहायक आचार्य/Assistant Professor

MedGenome Labs Ltd